NCT05339685进行中（未招募）1 期
Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of Injectable BL-M02D1 in Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer or Other Solid Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 82
- 试验地点
- 10
- 主要终点
- Phase Ib: Recommended Phase II Dose (RP2D)
研究概览
简要总结
In phase Ia study, the safety and tolerability of BL-M02D1 in patients with locally advanced or metastatic triple negative breast cancer or other solid tumors will be investigated to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) of BL-M02D1.
In phase Ib study, the safety and tolerability of BL-M02D1 at the phase Ia recommended dose will be further investigated, and recommended phase II dose (RP2D) for phase II clinical studies will be determined.
In addition, the preliminary efficacy, pharmacokinetic characteristics, and immunogenicity of BL-M02D1 in patients with locally advanced or metastatic triple negative breast cancer or other solid tumors will be evaluated.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants must sign the informed consent form voluntarily and follow the plan requirements.
- •No gender limit.
- •Age: ≥18 years old and ≤75 years old (phase Ia); ≥18 years old (phase Ib).
- •Expected survival time ≥ 3 months.
- •Locally advanced or metastatic gastrointestinal tumor and other solid tumor confirmed by histopathology and/or cytology, which are incurable or currently without standard treatment.
- •Participants must agree to provide archived tumor tissue specimens or fresh tissue samples of the primary tumor or metastasis; if the participant is unable to provide tumor tissue samples, the investigator will evaluate whether the participant could be enrolled if other criteria are fit to join the group.
- •Participants must have at least one assessable lesion in phase Ia; participants must have at least one measurable lesion that meets the definition of RECIST v1.1 in phase Ib.
- •Has an Eastern Cooperative Oncology Group performance status (ECOG PS) 0-1
- •Toxicity of previous antitumor therapy has returned to ≤ level 1 as defined by NCI-CTCAE v5.0 (except for asymptomatic laboratory abnormalities considered by the investigators, such as elevated ALP, hyperuricemia, and elevated blood glucose; Toxicities with no safety risk were excluded, such as alopecia, hyperpigmentation, and grade 2 peripheral neurotoxicity. Or except decreased hemoglobin but ≥90 g/L).
- •Has adequate organ function before registration, defined as: a) Bone marrow function: Absolute neutrophil count (ANC) ≥1.5×109/L, Platelet count ≥100×109/L, Hemoglobin ≥90 g/L; B) Hepatic function: Total bilirubin (TBIL≤1.5 ULN), AST and ALT ≤2.5 ULN for participants without liver metastasis, AST and ALT ≤5.0 ULN for liver metastases; c) Renal function: Creatinine (Cr) ≤1.5 ULN, or creatinine clearance (Ccr) ≥50 mL/min (according to the Cockcroft and Gault formula).
- •Coagulation function: International normalized ratio (INR)≤1.5×ULN, and activated partial thromboplastin time (APTT)≤1.5ULN.
- •Urinary protein ≤2+ or ≤1000mg/24h.
- •For premenopausal women with childbearing potential, a pregnancy test must be taken within 7 days prior to the start of treatment. Serum or urine pregnancy must be negative and must be non-lactating. Adequate barrier contraceptive measures should be taken during the treatment and 6 months after the end of treatment for all participants (regardless of male or female).
排除标准
- •Patients screened for any of the following conditions will not be included in this study:
- •Antitumor therapy such as chemotherapy, biotherapy, immunotherapy, radical radiotherapy, major surgery (as defined by the investigators), and targeted therapy (including small-molecule tyrosine kinase inhibitors) within 4 weeks prior to initial administration or within 5 half-lives, whichever is shorter; Mitomycin and nitrosourea were administered within 6 weeks before the first administration; Oral fluorouracil drugs such as Tizio, capecitabine, or palliative radiotherapy within 2 weeks before first administration; Traditional Chinese medicines with anti-tumor indications were administered within 2 weeks before the first dose.
- •Prior treatment with ADC drugs targeting TROP2 or ADC drugs using camptothecin derivatives (topoisomerase I inhibitors) as toxins.
- •Participants with history of severe heart disease, such as: symptomatic congestive heart failure (CHF) ≥ grade 2 (CTCAE 5.0), New York Heart Association (NYHA) ≥ grade 2 heart failure, history of transmural myocardial infarction, unstable angina pectoris etc.
- •Participants with prolonged QT interval (male QTc> 450 msec or female QTc> 470 msec), complete left bundle branch block, III grade atrioventricular block.
- •Active autoimmune diseases and inflammatory diseases, such as: systemic lupus erythematosus, psoriasis requiring systemic treatment, rheumatoid arthritis, inflammatory bowel disease and Hashimoto's thyroiditis, etc., except for type I diabetes, hypothyroidism that can be controlled only by alternative treatment, and skin diseases that do not require systemic treatment (such as vitiligo, psoriasis).
- •The presence of a second primary tumor within 5 years prior to initial administration, except for radical basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and/or radical resected carcinoma in situ.
- •Screening for unstable thrombotic events such as deep vein thrombosis, arterial thrombosis and pulmonary embolism requiring therapeutic intervention within the first 6 months; Infusion device-related thrombosis is excluded;
- •Patients with poorly controlled pleural effusion with clinical symptoms were judged by researchers to be unsuitable for inclusion.
- •Participants with poorly controlled hypertension by antihypertensive drugs (systolic blood pressure>150 mmHg or diastolic blood pressure>100 mmHg).
- •Lung disease defined as grade ≥3 according to CTCAE V5.0; ≥2 grade of radioactive lung disease, current or history of interstitial lung disease (ILD).
- •There are symptoms of active central nervous system metastasis. However, the researchers concluded that patients with stable brain parenchymal metastases could be included. Stable is defined as: a. The seizureless state persists for > 12 weeks with or without antiepileptic medication; b. Glucocorticoid use is not required; c. Two consecutive MRI scans (at least 4 weeks between scans) showed stable imaging status; d. Asymptomatic patients stable for more than 1 month after treatment.
- •Participants who have a history of allergies to recombinant humanized antibodies or human-mouse chimeric antibodies or any of the components of BL-M02D
- •Participants have a history of organ transplantation or allogeneic stem cell transplantation (Allo-HSCT).
- •In the adjuvant (or neoadjuvant) treatment of anthracyclines, the cumulative dose of anthracyclines is> 360 mg/m
- •Human immunodeficiency virus antibody (HIVAb) positive, active tuberculosis, active hepatitis B virus infection (HBV-DNA copy number> the lower limit of detection) or active hepatitis C virus infection (HCV antibody positive and HCV-RNA > the lower limit of detection).
- •Participants with active infections requiring systemic treatment, such as severe pneumonia, bacteremia, sepsis, etc.
- •Participated in another clinical trial within 4 weeks prior to participating in the study.
- •Pregnant or nursing women.
- •Other conditions that the investigator believes that it is not suitable for participating in this clinical trial.
研究组 & 干预措施
Study treatment
Experimental
Participants receive BL-M02D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
干预措施: BL-M02D1 (Drug)
结局指标
主要结局
Phase Ib: Recommended Phase II Dose (RP2D)
时间窗: Up to 21 days after the first dose
The RP2D is defined as the dose level chosen by the sponsor (in consultation with the investigators) for phase II study, based on safety, tolerability, efficacy, PK, and PD data collected during the dose escalation study of BL-M02D1.
Phase Ia: Dose limiting toxicity (DLT)
时间窗: Up to 21 days after the first dose
DLTs are assessed according to NCI-CTCAE v5.0 during the first cycle and defined as occurrence of any of the toxicities in DLT definition if judged by the investigator to be possibly, probably or definitely related to study drug administration.
Phase Ia: Maximum tolerated dose (MTD)
时间窗: Up to 21 days after the first dose
MTD is defined as the highest dose level at which no more than 1 in 6 participants experienced a DLT during the first cycle.
次要结局
- ADA (anti-drug antibody)(Up to approximately 24 months)
- Nab (neutralizing antibody)(Up to approximately 24 months)
- Disease Control Rate (DCR)(Up to approximately 24 months)
- Duration of Response (DOR)(Up to approximately 24 months)
- Treatment-Emergent Adverse Event (TEAE)(Up to approximately 24 months)
- Cmax(Up to 21 days after the first dose)
- T1/2(Up to 21 days after the first dose)
- CL (Clearance)(Up to 21 days after the first dose)
- Objective Response Rate (ORR)(Up to approximately 24 months)
- Tmax(Up to 21 days after the first dose)
- AUC0-t(Up to 21 days after the first dose)
- Ctrough(Up to 21 days after the first dose)
- Progression-free Survival (PFS)(Up to approximately 24 months)
研究者
研究点 (10)
Loading locations...
相似试验
进行中（未招募）
1 期
A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors or Other Solid TumorsLocally Advanced or Metastatic Digestive Tract TumorsSolid TumorNCT05385692Sichuan Baili Pharmaceutical Co., Ltd.22
进行中（未招募）
1 期
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid TumorsLocally Advanced or Metastatic Urinary TumorsOther Solid TumorsNCT05393427Sichuan Baili Pharmaceutical Co., Ltd.4
招募中
1 期
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid TumorLocally Advanced or Metastatic Solid TumorNCT05194982Sichuan Baili Pharmaceutical Co., Ltd.570
招募中
1 期
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid TumorGastrointestinal TumorNCT05262491Sichuan Baili Pharmaceutical Co., Ltd.96
招募中
1 期
A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2-Positive/Negative Breast Cancer and Other Solid TumorsLocally Advanced or Metastatic Solid TumorBreast CancerNCT05461768Sichuan Baili Pharmaceutical Co., Ltd.348